4B-MAR: First definitively identified in Austria in January 2022 and sold online as racemic trans-diastereomer (approximately 90% assay purity). No peer-reviewed pharmacodynamic studies yet exist; structure-activity relationships and subjective reports suggest potency slightly lower than 4-methylami
Related pages